Mucodis® Medical Device Launch

Quantum Pharma Plc

("Quantum" or the "Group")

Mucodis® Medical Device Launch

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that Colonis, part of its newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat some of the side effects of cancer treatment in patients.

This range initially comprises up to seven products that are used to treat the side effects of chemotherapy and radiotherapy, specifically the inflammation of different mucosal membranes of the body, including that of the mouth and rectum. The range will be marketed and sold in the UK under the Mucodis® brand name.

Some 330,000 patients in the UK are diagnosed with cancer every year and most suffer painful or unpleasant side effects as they progress with treatment. The Mucodis® range provides the NHS with prescribable products for a number of associated conditions, including mucositis, dermatitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for five years, with an option to extend beyond this initial period.

The first product in the range, Mucodis® Oromucosal Spray for the treatment of oral mucositis, a painful inflammation of the mouth that can follow certain typical cancer treatments, is launched today, with a preventative mouthwash expected to follow later this financial year. Of the 330,000 new instances of cancer in the UK every year, approximately 132,000 (40%) patients will typically develop some degree of oral mucositis as a result of standard treatment therapies. This figure is higher in paediatric oncology patients (90% of patients), as well as in patients receiving irradiation for neck and head cancers (97% of patients). Previously there have been limited options to manage this side effect. It is anticipated that additional Mucodis® products will be launched in the next financial year.

To support the launch of this range of products, Quantum has a specific therapeutic sales team in place, which has been active amongst oncology specialists, nurses and pharmacists establishing demand for these products. As a result of this, the entire first manufacturing batch of Mucodis® Oromucosal Spray has been bought by the pharmaceutical wholesale chain to ensure access for these prescribers.

Andy Scaife, CEO of Quantum Pharma, commented: "We are excited to be making available the first product in the Mucodis® range. This range has the potential to make a difference for patients living with the side effects of cancer treatment commonly triggered by radiotherapy and chemotherapy. The launch of Mucodis® and the developments within this team mark a promising new chapter for both Niche Pharmaceuticals and the Group's expansion into regulated products, with a number of further medical device and licensed product launches anticipated during the current financial year."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Niche Pharmaceuticals:

Comprising three business units which develop and supply niche pharmaceuticals, provide development and regulatory services and out-license products and dossiers to third parties across Europe.

Colonis® is a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda is a full service contract development specialist with customers across Europe. It specialises in creating added value products with distinct advantages for patients and health care providers, providing full services for the entire development chain - from inception to registration, to post approval finished product supply and regulatory support.

PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.

Specials:

Comprising four business units which manufacture, source and supply specials to pharmacies, pharmaceutical wholesalers, hospitals (NHS and private) and other specials suppliers throughout the UK and overseas.

Quantum Pharmaceutical manufactures and supplies specials and special obtains to pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

UL Medicines sources and supplies unlicensed imported medicines, batch made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development and clinical trials product manufacture.

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches for supply to private and NHS hospitals and homecare patients.

Medication Adherence:

Comprising two business units which provide products and services designed to enhance adherence to medication regimes:

Protomed which owns Biodose® a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. A telehealth version with the ability to remotely monitor medication adherence is in live testing.

Biodose Services assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

For further information, please visit www.quantumpharmagroup.com.